A looming shift in how Pakistan classifies imported medicines for customs purposes is sending alarm through the healthcare sector. Industry sources warn that long-standing tariff classifications are being questioned, with drugs historically imported under established headings now facing potential reclassification into residual categories that carry significantly higher duties and taxes. Main Developments Importers report a growing perception that revenue-driven challenges to tariff classifications are becoming more frequent. Products legally authorized by the Drug Regulatory Authority of Pakistan (DRAP) as medicines, and consistently classified under the same heading for decades, are now being proposed for placement under residual tariff headings with substantially higher customs duties and taxes. Industry sources emphasize that any abrupt departure from settled classification practice should be based on clear legal and scientific justification, not solely on revenue considerations. Tariff classification must remain consistent with the nature, characteristics, intended therapeutic use, and applicable legal provisions governing medicinal products. Read also: PPP accuses PML-N of rigging AJK polls, deepening Punjab debt Background The controversy stems from an ongoing effort by authorities to increase revenue collection through customs duties. Historically, medicines have benefited from established tariff classifications that kept duties manageable, supporting the availability of affordable healthcare products. DRAP's regulatory approval has been the traditional benchmark for classifying a product as a medicine. However, the current trend suggests that fiscal considerations are increasingly influencing classification decisions, potentially overriding scientific and legal criteria that have guided past practice. Why It Matters The consequences of imposing excessive customs duties on medicines extend far beyond the commercial interests of importers. Higher duties inevitably translate into higher retail prices, making medicines less affordable for patients. As costs rise, importers and manufacturers may find it economically impossible to continue supplying certain products. When a medicine becomes commercially non-viable, businesses are forced to discontinue imports or local production, resulting in shortages and disruption of the healthcare supply chain. The availability of medicines depends not only on regulatory approval but also on economic viability; a medicine that cannot be imported or manufactured at a sustainable cost is, in practical terms, no longer available to patients. Tax policies that unintentionally eliminate commercial viability ultimately undermine the very objective of ensuring a stable and continuous supply of healthcare products. A tax system that renders medicines commercially impossible to import or manufacture is ultimately self-defeating, as sustainable revenue is generated from a healthy, functioning economy—not from policies that eliminate the very businesses on which that revenue depends. What's Next Industry sources assert that this issue deserves immediate attention from DRAP, Pakistan Customs, the Federal Board of Revenue (FBR), the National Tariff Commission, the Ministry of Commerce, and representative trade bodies. A balanced approach that safeguards both public health and fiscal interests is essential. Without intervention, the trend could escalate, leading to more classification disputes and potential medicine shortages. The call for a coordinated response highlights the need for dialogue between regulators and the industry to ensure that revenue generation does not compromise access to essential medicines.